AzTrials
AzTrials

Pancreatic CancerPOWR-PaCNCT07772258

Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer

A study testing Corsano CardioWatch and Prehab4Cancer Programme in people with Pancreatic Cancer and Pancreatic Neoplasms, run by Manchester University NHS Foundation Trust.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Corsano CardioWatch and Prehab4Cancer Programme
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
No sites listed yet
Study dates
1 Oct 2026to 30 Sep 2028
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patients aged 18 years or older.
  • Able to provide informed consent.
  • Able to use the study devices independently or with support from a carer.
  • Approved for pancreatic cancer surgery, including patients undergoing surgery for:
  • Pancreatic cancer Distal cholangiocarcinoma Ampullary carcinoma Duodenal carcinoma Premalignant pancreatic lesions, including Intraductal Papillary Mucinous Neoplasms (IPMNs).
  • Clinically stable and considered suitable to participate in the prehabilitation and rehabilitation programme.
  • Owns a smartphone or tablet device

Who cannot join

  • Unable or unwilling to provide informed consent.
  • Lacks capacity to provide informed consent.
  • Unstable angina pectoris.
  • Recent myocardial infarction.
  • Recent cerebrovascular accident (stroke).
  • New cardiac arrhythmia.
Show all 10Show fewer
  • Social, physical, mental health, or substance misuse issues that, in the opinion of the investigator, would jeopardise adherence to study procedures or study contact.
  • No infrastructure for remote monitoring (no access to either mobile signal or Wi-Fi).
  • Clinically unstable or likely to require hospital admission within the next 72 hours.
  • Unable to use the study devices and no carer or support person is available to assist.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

Official title: Perioperative Optimisation and Wearable Remote Monitoring of Pancreatic Cancer

The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions.

The main questions it aims to answer are:

Read more

Does a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway?

Researchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes.

Participants will:

Provide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support.

Wear a Corsano CardioWatch device to continuously monitor physiological and activity data.

Use home monitoring equipment, including weight scales and blood pressure monitoring devices.

Complete questionnaires and participant logs during prehabilitation and recovery.

Receive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival.

Optionally participate in a focus group to discuss their experiences of wearable-enabled care.

Read the detailed description

POWR-PaC (Perioperative Optimisation and Wearable Remote monitoring of Pancreatic Cancer) is a prospective, single-centre study evaluating the integration of wearable technologies into an established perioperative prehabilitation and rehabilitation pathway for patients undergoing pancreatic surgery. The study is being conducted at Manchester University NHS Foundation Trust in partnership with the Greater Manchester Prehab4Cancer programme.

Major pancreatic surgery is associated with substantial morbidity, prolonged recovery, and significant variation in patient outcomes. Although prehabilitation programmes have demonstrated benefits for physical fitness and surgical preparedness, there is limited evidence regarding the role of continuous physiological monitoring and remote assessment throughout the perioperative pathway. Wearable technologies may provide objective, longitudinal measures of activity, sleep, cardiovascular function, recovery trajectories, and treatment tolerance that are not routinely captured during standard care.

Participants enrolled in the intervention arm will be prescribed the targeted Greater Manchester Prehab4Cancer pathway and will additionally receive a wearable monitoring package consisting of a Corsano CardioWatch device and supporting home monitoring equipment. Physiological and behavioural measures collected by the wearable system may include physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, sleep-related metrics, and other device-derived indicators. Weight and blood pressure measurements will also be collected using home monitoring equipment where applicable.

Data collection will occur across the perioperative pathway, including the pre-operative prehabilitation period, inpatient surgical admission, and post-operative rehabilitation phase. Clinical, functional, physiological, and patient-reported outcome measures will be collected alongside routinely recorded healthcare data. The study will evaluate data completeness, participant adherence, acceptability of remote monitoring, and the potential relationship between wearable-derived metrics and clinical outcomes.

A matched historical control cohort will be identified from electronic health records at Manchester University NHS Foundation Trust. Control participants will have undergone pancreatic surgery and standard perioperative care without participation in the wearable-enabled pathway. Matching methods will be used to minimise baseline differences between groups and support comparative analyses of clinical outcomes.

The primary clinical evaluation will focus on post-operative morbidity within 30 and 90 days of surgery. Secondary analyses will assess measures including mortality, hospital utilisation, days alive and out of hospital, functional recovery, quality of life, and engagement with prehabilitation and rehabilitation services. Exploratory analyses will investigate whether longitudinal wearable data can provide early indicators of recovery status, post-operative complications, or treatment response.

The study also incorporates a mixed-methods evaluation of implementation. Participants, healthcare professionals, and exercise specialists may be invited to take part in qualitative focus groups to explore experiences of wearable-supported care, barriers and facilitators to adoption, usability of the technology, and opportunities for future pathway optimisation. Qualitative findings will be used to inform the future design, implementation, and scale-up of digitally enabled perioperative pathways within NHS surgical services.

The findings from POWR-PaC will provide evidence regarding the feasibility, acceptability, and potential clinical value of integrating wearable technologies into perioperative cancer care and will inform the development of larger effectiveness studies and future digitally enabled surgical pathways.

Being tested
Corsano CardioWatch, Prehab4Cancer Programme
Keywords
Pancreatic Cancer, Pancreatic Surgery, Perioperative Care, Rehabilitation, Prehabilitation, Exercise, Nutrition, Wearables, Remote Monitoring, Digital Health, Mobile Health, Recovery of Function, Patient Monitoring, Telemedicine, Surgical Oncology, PROMS, Electronic Devices
Medical subject headings
Pancreatic Neoplasms, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Corsano CardioWatchDevice

    A wearable monitoring device used throughout the perioperative pathway to collect continuous physiological and activity data, including measures such as physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, and sleep-related metrics.

  • Prehab4Cancer ProgrammeBehavioural

    A personalised prehabilitation and rehabilitation programme comprising exercise, nutritional support, and wellbeing support delivered before and after pancreatic surgery.

Study groups in NCT07772258
Study groupRoleWhat they receive
Wearable-Enabled Prehabilitation and RehabilitationExperimentalParticipants undergoing pancreatic surgery will receive the Greater Manchester Prehab4Cancer programme supported by wearable monitoring, home physiological monitoring, and remote follow-up throughout the perioperative pathway. Outcomes will be compared with a propensity-score-matched historical cohort identified from routine electronic health records.
Receives: Device: Corsano CardioWatch; Behavioral: Prehab4Cancer Programme
Matched Historical Standard Care CohortNo interventionHistorical patients who underwent pancreatic surgery and received standard perioperative care without wearable monitoring. Participants will be identified retrospectively from electronic health records and matched to intervention participants using propensity score methods based on demographic and clinical characteristics. No study intervention will be delivered.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-operative complications

    Occurrence of post-operative complications following pancreatic surgery.

    Measured: 30 and 90 days post-surgery

Secondary outcomes (6)
  1. All-cause mortality

    All-cause mortality post-surgery

    Measured: 30, 90, 365 days post-surgery.

  2. Days Alive and Out of Hospital (DAOH)

    Number of days participants are alive and not admitted to hospital during the preoperative period (from enrolment to surgery) and during the postoperative recovery period. DAOH incorporates mortality, length of stay, and hospital readmissions into a single patient-centred outcome measure.

    Measured: From enrolment to date of surgery (preoperative period); and from date of surgery to 30, 90, and 365 days post-operatively (postoperative period).

  3. Length of Stay

    Number of days spent in hospital during the index surgical admission following pancreatic resection.

    Measured: From date of surgical resection to date of discharge from the index hospital admission, assessed up to 90 days post-surgery.

  4. Completeness of Wearable Data Collected via Corsano CardioWatch

    Percentage of expected physiological and activity data points (heart rate, SpO2, activity, sleep) successfully captured and transmitted, relative to the total expected monitoring period. Unit: percentage

    Measured: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.

  5. Participant Adherence to Wearable Device Wear Time

    Percentage of prescribed daily wear/use time achieved by participants. Unit: percentage

    Measured: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.

  6. Technical Feasibility of Wearable Device Data Collection

    Number of technical issues (device malfunction, connectivity failure, data transmission gaps) encountered with the Corsano CardioWatch. Unit: count

    Measured: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion31 Mar 2028 (estimated)
  4. Study completion30 Sep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07772258
Sponsor's protocol ID
B02760
Other IDs
ERP-2025-14388
Acronym
POWR-PaC
Status last verified
Aug 2026
First submitted
31 Jul 2026
Last updated
19 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data underlying the results reported in publications arising from this study may be shared in an anonymised form following completion of the study and publication of the primary results. Shared datasets may include demographic data, clinical characteristics, patient-reported outcome measures, wearable-derived physiological and activity data, and key outcome variables relevant to the published analyses. Data will be fully anonymised prior to sharing and no directly identifiable information will be released. Access will be subject to approval by Manchester University NHS Foundation Trust, compliance with applicable data sharing agreements, participant consent, UK GDPR, research governance requirements, and any relevant ethical approvals. Supporting documentation, including the study protocol, statistical analysis methods, and data dictionary, may also be made available where appropriate.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in